Search results
Results from the WOW.Com Content Network
Aribit (Aripiprazole) tablets. Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic [8] primarily used in the treatment of schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder; [8] other uses include as an add-on treatment for major depressive disorder and tic disorders. [8]
The approval of aripiprazole lauroxil from the Food and Drug Administration in 2015 was solely for the treatment of schizophrenia in adults. The ability to supplement aripiprazole lauroxil with oral supplements of aripiprazole allows for dosing flexibility, which is important for the treatment of schizophrenia, as symptoms and intensity of the disease vary greatly from patient to patient.
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), [1] [2] are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric ...
The second was when I intermittently peed blood over a 10-month stint. ... their anxiety symptoms. Therefore, men are more likely to develop severe symptoms of anxiety and possibly develop an ...
The first symptoms of neuroleptic malignant syndrome are usually muscle cramps and tremors, fever, symptoms of autonomic nervous system instability such as unstable blood pressure, and sudden changes in mental status (agitation, delirium, or coma). Other possible symptoms include sweating, trouble swallowing, tremors, incontinence, and mutism.
A growing body of research links marijuana use among some young adults to mental health issues such as schizophrenia, bipolar disorder and depression. ... 7 million men and women in Denmark over ...
A 2009 Advisory Committee to the U.S. Food and Drug Administration found that online anecdotal reports of discontinuation syndrome related to duloxetine included severe symptoms and exceeded prevalence of both paroxetine and venlafaxine reports by over 250% (although acknowledged this may have been influenced by duloxetine being a much newer ...
The consensus is to reduce dosage gradually over several weeks, e.g. 4 or more weeks for diazepam doses over 30 mg/day, [1] with the rate determined by the person's ability to tolerate symptoms. [120] The recommended reduction rates range from 50% of the initial dose every week or so, [121] to 10–25% of the daily dose every 2 weeks. [120]